Morepen Laboratories Limited has informed the Exchange about Amendment(s) in Business Transfer Agreement.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories' board, on May 12, 2025, signed an addendum to its Business Transfer Agreement (BTA) with subsidiary Morepen Medipath Limited, pushing the 'appointed date' for hiving off its Medical Devices Business from February 1, 2025 to April 1, 2025. The medical devices business is being transferred on a slump sale basis as a going concern, and the rest of the BTA remains unchanged. The board also approved audited FY25 results showing consolidated revenue of Rs. 1,829.94 crore (up ~7%) and net profit of Rs. 118.02 crore (up ~23% YoY), with EPS of Rs. 2.20 versus Rs. 1.88 last year. A final dividend of Rs. 0.20 per share (face value Rs. 2) was recommended. Additionally, subsidiary Morepen Medipath plans to set up a wholly owned subsidiary in Dubai to expand its medical device B2B and B2C business.
The BTA amendment is a minor date revision with no impact on the overall transaction, but the underlying medical devices divestment is a significant restructuring move. Strong FY25 consolidated earnings growth and the Dubai expansion signal business momentum, while the small dividend (yield modest) reflects routine capital returns.